Latest Insider Transactions at Aligos Therapeutics, Inc. (ALGS)
This section provides a real-time view of insider transactions for Aligos Therapeutics, Inc. (ALGS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aligos Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aligos Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 25
2023
|
Lawrence Blatt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
610,277
+24.83%
|
$0
$0.76 P/Share
|
|
Oct 25
2023
|
Carole Nuechterlein |
BUY
Open market or private purchase
|
Indirect |
7,933,601
+41.84%
|
$0
$0.76 P/Share
|
|
Oct 25
2023
|
James Paul Scopa |
BUY
Grant, award, or other acquisition
|
Direct |
183,083
+50.0%
|
$0
$0.76 P/Share
|
|
Jun 11
2021
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Direct |
2,226
+33.33%
|
-
|
|
Jun 11
2021
|
Thomas Woiwode Director |
SELL
Other acquisition or disposition
|
Indirect |
504,081
-75.0%
|
-
|
|
Jun 11
2021
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Indirect |
18,102
+50.0%
|
-
|
|
Apr 26
2021
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Direct |
2,226
+50.0%
|
-
|
|
Apr 26
2021
|
Thomas Woiwode Director |
SELL
Other acquisition or disposition
|
Indirect |
504,084
-73.33%
|
-
|
|
Apr 26
2021
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Indirect |
18,105
+50.0%
|
-
|
|
Oct 20
2020
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,906,191
+36.53%
|
-
|
|
Oct 20
2020
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+7.11%
|
$3,000,000
$15.0 P/Share
|
|
Oct 20
2020
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,414,563
+50.0%
|
-
|
|
Oct 20
2020
|
Leonid Beigelman President |
BUY
Conversion of derivative security
|
Indirect |
273,057
+25.02%
|
-
|
|
Oct 20
2020
|
Lawrence Blatt Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
273,058
+29.94%
|
-
|
|
Oct 20
2020
|
Carole Nuechterlein |
BUY
Conversion of derivative security
|
Indirect |
3,092,340
+25.83%
|
-
|
|
Oct 20
2020
|
Lucinda Y. Quan |
BUY
Conversion of derivative security
|
Indirect |
9,258
+24.62%
|
-
|
|
Oct 20
2020
|
Julian A. Symons |
BUY
Conversion of derivative security
|
Direct |
18,517
+1.54%
|
-
|
|
Oct 20
2020
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+18.82%
|
$3,000,000
$15.0 P/Share
|
|
Oct 20
2020
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
662,444
+36.53%
|
-
|
|
Oct 20
2020
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,429,895
+20.4%
|
-
|
|
Oct 20
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
550,000
+13.42%
|
$8,250,000
$15.0 P/Share
|
|
Oct 20
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,997,030
+25.23%
|
-
|
|
Oct 20
2020
|
Thomas Woiwode Director |
BUY
Open market or private purchase
|
Indirect |
200,000
+18.82%
|
$3,000,000
$15.0 P/Share
|
|
Oct 20
2020
|
Thomas Woiwode Director |
BUY
Conversion of derivative security
|
Indirect |
3,092,339
+26.85%
|
-
|